Memorial Sloan Kettering Bergen
Montvale, NJ
Accepting patients
Cabozantinib
A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- Tyrosine Kinase (TK) Inhibitor
- Phase 2
- Has results
Accepting patients
Avutometinib and Defactinib
Phase II of Avutometinib (VS-6766) and Defactinib In RAF Dimer-Driven RAI-Refractory Differentiated and Anaplastic Thyroid Cancer Patients
- MEK Inhibitor
- Focal Adhesion Kinase (FAK) Inhibitor
- Phase 2